Dr Sundar Jagannath speaks to ecancer about the results from the LINKER-MM1 clinical trial, testing the safety and efficacy of linvoseltamab (a B-cell maturation antigen × CD3 antibody) as a treatment for relapsed/refractory multiple myeloma (RRMM).

The primary endpoint of this study was objective response rate per Independent Review Committee (IRC).

Secondary endpoints included duration of response, progression free survival, overall survival, and safety.

The study found that linvoseltamab induced high rates of deep and durable responses in patients with RRMM including those in high-risk subgroups.